Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1962 1
1967 1
1971 1
1972 4
1973 5
1974 2
1975 4
1977 1
1978 1
1979 5
1980 4
1981 2
1982 5
1983 6
1984 8
1985 10
1986 9
1987 7
1988 6
1989 8
1990 17
1991 13
1992 15
1993 16
1994 14
1995 19
1996 10
1997 7
1998 5
1999 8
2000 5
2001 5
2002 9
2003 9
2004 17
2005 19
2006 14
2007 10
2008 15
2009 11
2010 23
2011 15
2012 9
2013 20
2014 14
2015 15
2016 11
2017 18
2018 10
2019 19
2020 14
2021 23
2022 20
2023 23

Text availability

Article attribute

Article type

Publication date

Search Results

528 results

Results by year

Filters applied: . Clear all
Page 1
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA. Wang ML, et al. Among authors: williams me. N Engl J Med. 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19. N Engl J Med. 2013. PMID: 23782157 Free PMC article. Clinical Trial.
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
Rusconi C, Cheah CY, Eyre TA, Tucker D, Klener P, Giné E, Crucitti L, Muzi C, Iadecola S, Infante G, Bernard S, Auer RL, Pagani C, Duglosz-Danecka M, Mocikova H, van Meerten T, Cencini E, Marin-Niebla A, Williams ME, Angelillo P, Nicoli P, Arcari A, Morello L, Mannina D, Vitagliano O, Sartori R, Chiappella A, Sciarra R, Stefani PM, Dreyling M, Seymour JF, Visco C. Rusconi C, et al. Among authors: williams me. Blood. 2022 Oct 27;140(17):1907-1916. doi: 10.1182/blood.2022015560. Blood. 2022. PMID: 35789260
Hyperkalemia.
Williams ME, Rosa RM, Epstein FH. Williams ME, et al. Adv Intern Med. 1986;31:265-91. Adv Intern Med. 1986. PMID: 3511620 Review. No abstract available.
Geriatric assessment.
Williams ME. Williams ME. Ann Intern Med. 1986 May;104(5):720-1. doi: 10.7326/0003-4819-104-5-720. Ann Intern Med. 1986. PMID: 3963668 No abstract available.
Inorganic biomimetic nanostructures.
Levine LA, Williams ME. Levine LA, et al. Among authors: williams me. Curr Opin Chem Biol. 2009 Dec;13(5-6):669-77. doi: 10.1016/j.cbpa.2009.09.004. Epub 2009 Oct 7. Curr Opin Chem Biol. 2009. PMID: 19818676 Review.
Electronic databases.
Williams ME. Williams ME. Science. 1985 Apr 26;228(4698):445-50, 455-6. doi: 10.1126/science.3885395. Science. 1985. PMID: 3885395
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Zhang L, Baher L, Cheng M, Lee D, Beaupre DM, Rule S. Wang ML, et al. Among authors: williams me. Blood. 2015 Aug 6;126(6):739-45. doi: 10.1182/blood-2015-03-635326. Epub 2015 Jun 9. Blood. 2015. PMID: 26059948 Free PMC article. Clinical Trial.
Endocrine crises. Hyperkalemia.
Williams ME. Williams ME. Crit Care Clin. 1991 Jan;7(1):155-74. Crit Care Clin. 1991. PMID: 2007212 Review.
The patient profile.
WILLIAMS ME. WILLIAMS ME. Nurs Res. 1960;9:122-4. Nurs Res. 1960. PMID: 13844901 No abstract available.
528 results